SCHEMBL26097698

SCHEMBL26097698

O=S(=O)(N1CCOCC1)N1CC(c2ccccc2F)CC1CBr

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GLRA3 O75311 1/20 0.36
GLRB P48167 1/20 0.36
TSHR P16473 3/20 0.35
GAA P10253 2/20 0.35
POLB P06746 2/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 3/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
MEN1 O00255 1/20 0.33
PKM P14618 1/20 0.33
KMT2A Q03164 1/20 0.33
CYP2A13 Q16696 1/20 0.33
ADAM10 O14672 1/20 0.33
MMP2 P08253 1/20 0.33
MMP3 P08254 1/20 0.33
MMP9 P14780 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26532480 1.00 NPC1 (0.40) NPC1ALDH1A1SMN1; SMN2GLRA3GLRB
SCHEMBL26098035 1.00 NPC1 (0.40) NPC1ALDH1A1SMN1; SMN2GLRA3GLRB
SCHEMBL26100311 0.89 NPC1 (0.42) NPC1ALDH1A1SMN1; SMN2GLRA3GLRB
SCHEMBL26100306 0.89 NPC1 (0.42) NPC1ALDH1A1SMN1; SMN2GLRA3GLRB
SCHEMBL26910599 0.86 NPC1 (0.42) NPC1ALDH1A1SMN1; SMN2TSHRGAA
SCHEMBL26910567 0.86 SLC6A9 (0.34) GLRA3GLRB
SCHEMBL26910561 0.86 SLC6A9 (0.34) GLRA3GLRB
SCHEMBL26100676 0.84 LMNA (0.40) ALDH1A1SMN1; SMN2TSHRGAAPOLB
SCHEMBL26099322 0.84 LMNA (0.40) ALDH1A1SMN1; SMN2TSHRGAAPOLB
SCHEMBL26910574 0.82 SMN1; SMN2 (0.39) NPC1ALDH1A1SMN1; SMN2LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4422618-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS Anovia Biosciences, Inc. (US) 2024-09-04 EP disclosed
US-12016864-B2 LOX enzyme inhibiting methods and compositions ANOVIA BIOSCIENCES, INC. (US) 2024-06-25 US disclosed
US-20230390299-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS ANOVIA BIOSCIENCES INC (US) 2023-12-07 US disclosed
WO-2023076567-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS ANOVIA BIOSCIENCES, INC. (US) 2023-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230390299-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS LOX, LOXL1, LOXL2 NPC1 2040/4885ALDH1A1 646/4885SMN1; SMN2 3180/4885
US-12016864-B2 LOX enzyme inhibiting methods and compositions LOX, LOXL1, LOXL2 NPC1 1494/4885ALDH1A1 130/4885SMN1; SMN2 1926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.